1.59 lakh people have invested in this fund
1.59 lakh people have invested
in this fund as of
Total AUM
₹2,755.75 crores as of Jul 31, 2024
Age of Fund
5 years 9 months since Nov 30, 2018
Expense Ratio
1.94% as of Aug 30, 2024
Exit Load
0.5% If redeemed between 0 - 1 Months
Ideal holding period
10 Years+
Holdings
as of Jul 31, 2024Sun Pharmaceutical Industries Limited
11.70%
Suven Pharmaceuticals Limited
10.47%
Cipla Limited
7.77%
IPCA Laboratories Limited
7.61%
Lupin Limited
7.58%
Alembic Pharmaceuticals Limited
6.09%
Globus Medical Inc
5.09%
Small Cap
40.40%
Large Cap
28.50%
Mid Cap
19.00%
Uncategorized
11.90%
Pharmaceuticals & Biotechnology
Healthcare Services
Healthcare Equipment & Supplies
Insurance
Retailing
Rolling Returns
Chirag Dagli
Prescribed asset allocation: 80% - 100% Equity and equity related securities of pharmaceutical and healthcare companies , 0% - 20% Equity and Equity related securities of other Companies , 0% - 20% Debt, securitized debt and Money Market Securities , 0% - 10% Units of REITs & InvITs
Top holdings
Sun Pharmaceutical Industries Limited
11.70%
Suven Pharmaceuticals Limited
10.47%
Cipla Limited
7.77%
IPCA Laboratories Limited
7.61%
Lupin Limited
7.58%
Allocation by Market Cap
Small Cap
40.40%
Large Cap
28.50%
Mid Cap
19.00%
Uncategorized
11.90%
Top Sectors
Pharmaceuticals & Biotechnology
Healthcare Services
Healthcare Equipment & Supplies
Insurance
Mutual-funds
Top holdings
No Data to display
Top holdings
TREPS / Reverse Repo Investments
2.20%
Cash & cash equivalents
1.12%
Instrument break-up
TREPS
100.00%
Portfolio turnover ratio
0.10 last 12 months
Standard Deviation
15.96 %
Sharpe Ratio
0.75
Beta
0.94
R-Squared
89.28 %
Performance highlights over last
for
investment
Cumulative returns on
Annual returns
Current value
Historical Returns (As per SEBI format)as of with investment of₹10,000
This fund | BSE HEALTHCARE (TRI) ^ | NIFTY 50 TRI # | ||||
---|---|---|---|---|---|---|
CAGR | Current Value | CAGR | Current Value | CAGR | Current Value |
Income distribution Cum Capital Withdrawal (IDCW) Distributed
Record Date | IDCW per unit | NAV Before | NAV After |
---|
Funds | Annual returns | Current Value | Absolute Growth |
---|
Date of allotment: Nov 30, 2018.
Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement
Different plans shall have a different expense structure. The performance details provided herein are of Regular Plan.
Since inception returns have been calculated from the date of allotment till June 30, 2021
Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments
Rolling returns have been calculated based on returns from regular plan growth option.
^ Fund Benchmark # Additional Benchmark
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
There is no assurance that the investment objective of the Scheme will be realized
An open ended equity scheme investing in healthcare and pharmaceutical sector
Level of Risk in the fund
Rs. 100 Lumpsum
Rs. 100
SIP– 12 instalments
Rs. 100 Minimum Additional Purchase
1.59 lakh peoplehave invested in this fund as of